Cargando…

Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia

Here we present the 3-year results of ZUMA-4, a phase I/II multicenter study evaluating the safety and efficacy of KTEX19, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in pediatric/adolescent patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Phase I ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Wayne, Alan S., Huynh, Van, Hijiya, Nobuko, Rouce, Rayne H., Brown, Patrick A., Krueger, Joerg, Kitko, Carrie L., Dela Ziga, Edward, Hermiston, Michelle L., Richards, Michael K., Baruchel, Andre, Schuberth, Petra C., Rossi, John, Zhou, Lang, Goyal, Lovely, Jain, Rajul, Vezan, Remus, Masouleh, Behzad Kharabi, Lee, Daniel W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973494/
https://www.ncbi.nlm.nih.gov/pubmed/36263840
http://dx.doi.org/10.3324/haematol.2022.280678

Ejemplares similares